ITI Life Sciences commits £30 million to new R&D programme
New company - Stirling Medical Innovations - established to develop near-patient and home use diagnostic tests based on novel biomarker technologies
02-Mar-2005 -
ITI Life Sciences announced it has committed £30 million as part of a new three-year R&D programme focused on the development of new near-patient and home use diagnostic tests. Initially, the programme will focus on developing near-patient tests based on novel biomarkers (indicators) for ...
biomarker
biomarkers
cardiovascular diseases
+4